CytRx OverviewLatest common stock for CYTR: $500K.
Get informed when a big investor buys or sells
+ Follow
Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
CytRx posts a common stock of $500K as of March 2025. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
Common Stock is one piece of CytRx's financial statement story. At $500K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for CYTR's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; CytRx's other metric pages and overview cover the third.
Judging CytRx against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in common stock easier to interpret. Start with $500K here, then scan peer and history charts to see if the gap is persistent.
